- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05504499
REFINE Study: A Study In a Novel Interspinous Fusion Device In Subjects With Low Back Pain (Refine)
REFINE Study: A Prospective, Observational, Open-Label, Non-Randomized, Multi-Center Study Measuring Functional Outcomes In a Novel Interspinous Fusion Device In Subjects With Low Back Pain
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
INTRODUCTION
This study will evaluate the effectiveness and safety of the use of Aurora Spine ZIP™ MIS Interspinous Fusion System and bone graft material in single-level fusion in patients with chronic low back pain that present with degenerative disc disease (DDD) with concurrent neurogenic claudication.
Devices included in study are the Aurora Spine ZIP™ MIS Interspinous Fusion System and bone graft material. The device is a bilateral locking plate system which attaches to the spinous processes of the posterior noncervical spine (T1-S1) from an interlaminar approach. The implants have superior and inferior spinous process articulations and a central bone graft chamber.
The Aurora Spine ZIP™ is used to treat DDD (defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies), spondylolisthesis, trauma (i.e., fracture or dislocation), and/or tumor. The studied indication is lumbar degenerative disease resulting in back pain with lower extremity symptoms and neurogenic claudication.
Degenerative disc disease is a common condition of the aging spine, and may contribute to a variety of painful symptoms, including radiculopathy, neurogenic claudication, and back pain. There are a number of mechanical sequelae that result from these degenerative processes of the intervertebral disc, which may manifest in the anterior, middle, and posterior columns of the spine. Symptoms of degenerative disc disease have traditionally been treated with a variety of conservative (pain medications, physical therapy, epidural steroid injections) and invasive (surgical decompression and/or fusion) options(1,2). Interspinous spacers (ISS) have been proven to be effective for neurogenic claudication with 5 year outcome data and robust clinical experience (3). More invasive treatment options for lumbar spinal stenosis include decompressive laminectomies and a variety of approaches to lumbar fusion.
Direct comparison of two year results of ISS and decompressive laminectomies found ISS offers a less invasive treatment that reduces the potential for comorbidities, necessity for future operations, and is less disruptive to the spinal anatomy providing greater options for future surgical interventions with equivalent clinical outcomes (4). The landmark multicenter SPORT trial compared decompressive laminectomy to conservative non-operative care in patients with spinal stenosis with neurogenic claudication and found that the surgical group had significantly greater improvement in pain and function at four-year follow-up (5).
A meta-analysis of lumbar fusions for degenerative diseases looked at patient reported outcomes from 65 studies including disability, pain scores, and patient satisfaction. Fusion has been shown to be evidenced for spondylolisthesis, and patients who were randomly assigned to fusion care were 4 times as likely to be satisfied, attained 34% greater pain relief and saw a 40% improvement of preoperative disability when compared to those who received non-operative care (2). Evidence for fusion for stenosis without spondylolisthesis is limited in this meta-analysis, however this did not distinguish among fusion approaches.
Fusion did provide greater relief than non-operative care in patients with chronic low back pain without clinically significant stenosis or spondylolisthesis (2). Five randomized control trials reported results with fusion between 16-18% improved in terms of back and leg pain as compared to non-operative care (2). Anterior interbody fusion (ABF) and posterolateral fusion with pedicle screws (PLF) in patients with discogenic low back pain resulted in a significant decrease in VAS pain scores, with greatest relief following ABF, compared to conservative treatment (6).
3 STUDY PURPOSE
The purpose of this study is to evaluate the effectiveness and safety of the use of Aurora Spine ZIP™ MIS Interspinous Fusion System and bone graft material in single-level fusion in patients with chronic low back pain that present with degenerative disc disease with concurrent neurogenic claudication.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Shelley Trimm, BS
- Phone Number: 7075085527
- Email: strimm@pacificresearchinstitute.care
Study Contact Backup
- Name: Kam Murrell
- Phone Number: 267.818.9024
- Email: kmurrell@pacificresearchinstitute.care
Study Locations
-
-
California
-
Santa Rosa, California, United States, 95403
- Active, not recruiting
- Evolve Restorative Center
-
-
Florida
-
Jupiter, Florida, United States, 33477
- Recruiting
- The Raso Pain Center
-
Contact:
- Jodie Laprade
- Phone Number: 561-264-2929
- Email: teamrasojodie@aol.com
-
Principal Investigator:
- Louis Raso, MD
-
-
Louisiana
-
Slidell, Louisiana, United States, 70458
- Recruiting
- Koga Neurosurgery
-
Contact:
- Rachel Englert, RN
- Phone Number: 985-269-7676
- Email: rachel@koga.clinic
-
Principal Investigator:
- Sebastian Koga, MD
-
-
Maryland
-
Oxon Hill, Maryland, United States, 20745
- Recruiting
- National Spine and Pain Centers
-
Principal Investigator:
- Vipul Mangal, MD
-
Contact:
- Diamond Wilson
- Phone Number: 301-485-7400
- Email: DWilson@treatingpain.com
-
-
Nevada
-
Henderson, Nevada, United States, 89509
- Recruiting
- Comprehensive & Interventional Pain Management
-
Principal Investigator:
- Rainer Vogel, MD
-
Contact:
- Shepard Urban
- Phone Number: 702-990-4530
- Email: shepardurbahnpac@cipmnv.com
-
Reno, Nevada, United States, 20745
- Recruiting
- Nevada Advanced Pain Specialists
-
Contact:
- Rachel Yetter
- Phone Number: 775-284-8650
- Email: rachael@nvadvancedpain.com
-
Principal Investigator:
- Denis Patterson, DO
-
Reno, Nevada, United States, 89509
- Recruiting
- Reno Tahoe Pain Associates
-
Contact:
- Maria Peregrina
- Phone Number: 775-236-8596
- Email: peregrina@rtpain.net
-
Principal Investigator:
- Ali Nairizi, MD
-
-
New Jersey
-
Voorhees, New Jersey, United States, 08043
- Recruiting
- The Pain Management Center
-
Contact:
- Onoshoze Bossey
- Phone Number: 609-382-0392
- Email: Onoshoze.Bossey@prospirapc.com
-
Principal Investigator:
- Youseff Josephson, MD
-
-
Ohio
-
Loveland, Ohio, United States, 45140
- Recruiting
- Premier Pain Treatment Institute
-
Principal Investigator:
- Michael Danko, MD
-
Contact:
- Kathy White
- Phone Number: 513-454-7246
- Email: kwhite@premierpaintreatment.com
-
-
Pennsylvania
-
Chadds Ford, Pennsylvania, United States, 17601
- Recruiting
- Center for Interventional Pain and Spine
-
Contact:
- Ashley Scherer
- Phone Number: 844-365-7246
- Email: ashleys@centerisp.com
-
Contact:
- Ashley K
- Phone Number: 844.365.7246
- Email: ashleyk@centerisp.com
-
Principal Investigator:
- Steven Falowski, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Subjects enrolled in this study must meet ALL of the following inclusion criteria:
- Subject must provide written informed consent prior to any clinical study-related procedure.
- Subject is at least 18 years or older at the time of enrollment, skeletal mature.
- Subject has 1-2 symptomatic lumbar degenerative disease at adjacent level, T12-S1, with or without grade I spondylolisthesis (confirmed by history and radiographic studies).
- MRI within 12 months prior to the procedure with at least mild to moderate spinal stenosis at the index treatment level
- Subject has undergone at least 3 months of non-operative treatment.
- Subject presents with ZCQ physical function ≥ 2.0 at baseline.
- Subject reports relief from lumbar flexion and/or sitting.
- Subject has baseline VAS of back and/or leg pain standing or walking ≥ 50mm.
Exclusion Criteria:
Subjects enrolled in this study must NOT meet any of the following exclusion criteria:
- Subject is unable to provide written informed consent.
- Subject has had previous lumbar spine surgery at the intended treatment level (e.g., laminectomy or fusion).
- Subject has a grade II or greater spondylolisthesis on flexion and extension radiographs with 3mm instability.
- Subject has confirmed or suspected osteoporosis or osteopenia.
- Subject is enrolled, or intends to participate, in a clinical drug and/or device study (investigational device, investigational drug, new indication for a device or drug, or additional testing beyond standard of care procedures) which could confound the results of this trial as determined by the investigator.
- Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements.
- Subject is pregnant or nursing.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single Arm
A Prospective, Open-Label, Non-Randomized, Multi-Center Study Measuring Functional Outcomes In a Novel Interspinous Fusion Device In Subjects With Low Back Pain A Prospective, Observational, Open-Label, Non-Randomized, Multi-Center Study Measuring Functional Outcomes In a Novel Interspinous Fusion Device In Subjects With Low Back Pain
|
The intended study population are adults 18 years or older with symptomatic lumbar degenerative disc disease resulting in back pain with lower extremity symptoms and neurogenic claudication that improves with spinal flexion who are candidates for use of the Zip™ MIS Interspinous Fusion device when undergoing spinal fixation procedures.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate the efficacy and safety of the Aurora Spine ZIP™ MIS Interspinous Fusion System and bone graft material based on improvement in composite endpoints relative to baseline at 3 and 12 months 1. > 20mm pain reduction in VAS Back while standing
Time Frame: 12 months
|
The primary composite endpoint is individual patient success from baseline at 3- and 12-months of follow-up, which will be assessed as follows:
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
• To demonstrate real-world evidence of a significant improvement in the Pain Impact Score using ZIP™ as measured by the PROMIS-29 relative to baseline at 3 and 12 months.
Time Frame: 12 months
|
|
12 months
|
• To identify patterns related to the influence of pharmacologic agents on response to therapy (and vice versa).
Time Frame: 12 months
|
Change in use of pain medications related to initial lumbar pathology
|
12 months
|
To characterize patient global impression of change (PGIC) relative to baseline at 3 and 12 months.
Time Frame: 12 months
|
Subjects will be asked if their overall pain since study treatment was very much improved, much improved, minimally improved, no change, minimally worse, much worse or very much worse
|
12 months
|
Imaging analysis
Time Frame: 12 months
|
Xray 12 months
|
12 months
|
Complication Rate
Time Frame: 12 months
|
No major implant or procedure-related complications
|
12 months
|
Complication Rate
Time Frame: 12 months
|
Spinous process fracture rate
|
12 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AUR-ZIP-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lumbar Spinal Stenosis
-
Johns Hopkins UniversityNorth American Spine SocietyCompletedLumbar Spinal Stenosis | Lumbar Spine Degeneration | Lumbar Spinal InstabilityUnited States
-
Azienda Usl di BolognaRecruitingLumbar Spinal Stenosis | Degenerative Lumbar Spinal StenosisItaly
-
Medipol UniversityWithdrawnLumbar Spinal Stenosis | Lumbar Disc Disease | Lumbar Spine Degeneration | Lumbar Spine InstabilityTurkey
-
University Hospital, Basel, SwitzerlandKlinik für Radiologie und Nuklearmedizin, University Hospital BaselCompletedLumbar Spinal Stenosis | Symptomatic Lumbar Spinal StenosisSwitzerland
-
Xuanwu Hospital, BeijingRecruitingLumbar Disc Herniation | Lumbar Spinal Stenosis | Lumbar SpondylosisChina
-
Bursa City HospitalCompletedLumbar Spinal Stenosis | Lumbar Spine Degeneration | Lumbar Spine InstabilityTurkey
-
Neurocenter of Southern SwitzerlandMaastricht University; Schulthess KlinikRecruitingLumbar Spinal Stenosis | Lumbar Spondylolisthesis | Spinal Disease | Lumbar InstabilitySwitzerland
-
Cantonal Hospital of St. GallenProf. Dr. Astrid Weyerbrock, Klinik für Neurochirurgie, Kantonsspital St.... and other collaboratorsCompletedLumbar Spinal Stenosis | Lumbar Disc Disease | Lumbar Spine DegenerationSwitzerland
-
University of Roma La SapienzaRecruitingLumbar Spinal Stenosis | Lumbar Spondylolisthesis | Lumbar Spine Degeneration | Lumbar Spine InstabilityItaly
-
Kyungpook National University HospitalCompletedDisk Herniated Lumbar | Spinal Stenosis LumbarKorea, Republic of
Clinical Trials on Interspinous Fusion
-
Spinal Simplicity LLCThe Leeds Teaching Hospitals NHS TrustCompletedDegenerative Disc Disease | Lumbar Spinal Stenosis | SpondylolisthesisUnited Kingdom
-
Synthes USA HQ, Inc.TerminatedSpinal StenosisUnited States
-
Globus Medical IncTerminatedLumbar Spinal StenosisUnited States
-
Centre Hospitalier Universitaire de NiceCompletedDegenerative Lumbar Spinal Stenosis | Neurologic Intermittent ClaudicationFrance
-
University Hospital of PatrasSt. Andrew's General Hospital, Patras, GreeceCompletedAdjacent Segment Degeneration
-
Non-Linear TechnologiesUnknownLumbar Spinal StenosisCzech Republic
-
Diametros Medical srlMCRA; Sciently di Omar Sabry; Medical Consulting srlRecruitingClaudication, Intermittent | Spinal Lumbar StenosisItaly
-
Medtronic Spine LLCCompletedLumbar Spinal StenosisUnited States
-
Medtronic Spinal and BiologicsCompletedSpinal StenosisGermany, Belgium, United Kingdom
-
Zimmer SpineZimmer BiometUnknown